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Engineered protein cages for selective heparin
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A heparin-specific binding peptide was conjugated to a cowpea
chlorotic mottle virus (CCMV) capsid protein, which was sub-
sequently allowed to encapsulate heparin and form capsid-like
protein cages. The encapsulation is specific and the capsid-
heparin assemblies display negligible hemolytic activity, indicating
proper blood compatibility and promising possibilities for heparin
antidote applications.
Heparin (Fig. 1a) is a highly anionic polysaccharide belonging
to the family of glycosaminoglycans and is widely used as an
anticoagulant in surgical practices and thrombotic events.1 The
anticoagulant activity is based on its ability to bind and sub-
sequently activate antithrombin-III, which leads to the inactivation
of vital coagulation cascade substances such as thrombin and
factor Xa.2 For safe clinical operation, heparin requires an anti-
dote, which can counteract the anticoagulant effect and suppress
potential side effects, if needed.3 Protamine sulfate is a small
arginine-rich cationic protein that binds heparin via electrostatic
interactions, and is commonly used for this purpose.2,4 This
interaction is electrostatic in nature, but nonspecific, and
protamine sulfate can cause multiple adverse effects.5 This
has initiated diverse attempts to develop safer heparin anti-
dotes, such as cationic polymers and small molecules, which all
largely rely on the electrostatic binding with heparin.6–12
Although efficient binding can be achieved, cationic platforms
often lack specificity to heparin and usually exhibit high cyto-
toxicity. Furthermore, the complexes formed with heparin are often
large and ill-defined aggregates. Therefore, more sophisticated
alternatives that would transform heparin into small and well-
defined particles, which are biologically inert, are needed.9,12
Virus-like particles (VLPs) are protein assemblies derived
from wild-type viruses. They lack the viral genome but have
similar well-defined capsid structures as native virus particles,
and have therefore been explored for biomedical and nano-
technological applications.13–17 Indeed, their most appealing
features are the accurate sizes and shapes, which are combined
with a relatively high stability and versatile modification
potential.18 The removal of the viral genome also generates a highly
confined cavity, which can be harnessed to compartmentalize other
nanoscale substances.19–21 Cowpea chlorotic mottle virus (CCMV)
capsid is one of the most studied VLPs as they can be produced in
high yields22 and undergo pH and ionic strength-dependent
swelling and assembly,23,24 which have therefore been intensively
utilized in cargo-loading.25
In more detail, CCMV is a plant-infecting icosahedral virus
consisting of 180 capsid proteins (CPs) in its native T = 3 form,
leading to a capsid with an outer diameter of 28 nm and an
inner cavity diameter of 18 nm (Fig. 1b).26 Its T = 1 and pseudo
T = 2 forms consist of 60 and 120 capsid proteins and have
diameters of roughly 18 and 22 nm, respectively.27 Each CP is
formed from 190 amino acids with its N-terminus located on
the interior of the capsid. CCMV can be modified in multiple
different ways, for example, by functionalizing carboxylic acids
or amines on the exterior of the capsid.28,29 In addition, the
CCMV interior may be altered to enable enhanced cargo loading
and encapsulation through electrostatic interactions.30,31 To
obtain a highly defined modification of the capsid interior, an
appealing approach is to engineer the N-termini, which provides
site- and number-specificity. For this purpose, an enzymatic
method involving a reaction catalyzed by the enzyme Sortase A
(SrtA) has been developed.32 This benign methodology was first
utilized to label the CCMV capsids with a fluorescent tag, but
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due to the generic nature of the strategy, a wide range of cargos
loaded in VLPs can be envisioned.33,34
So far, only the exteriors of virions have been employed to
display polycationic motifs (poly-Arg) for heparin-binding.35–38
However, multiple mutations may yield unstable virions and
lead to nonspecific electrostatic interactions with heparin. In
this work, we report on the conjugation of a heparin-binding
peptide (HBP), i.e. a heparin-specific sequence derived from
the fibroblast growth factor having a dissociation constant of
B134 pM with heparin, to the interior of the CCMV capsid.39
The binding and packing of heparin into the protein cage was
studied with dynamic light scattering (DLS), transmission
electron microscopy (TEM), and fast protein liquid chromato-
graphy (FPLC). Assemblies were not observed in the presence of
two other glycosaminoglycan analogues, demonstrating high
selectivity towards heparin. Moreover, no hemolytic activity was
detected, implying proper biocompatibility.
The particular HBP was selected based on its high selectivity
and affinity to heparin, thus minimizing off-target binding even
in complex biological environments.12,39 Conjugation of HBP to
the CP N-terminus was realized with the SrtA-based method, as
illustrated in Fig. 1c. SrtA catalyzes the cleavage of the HBP
C-terminal sorting signal (LPETG) after threonine and the
subsequent ligation with an N-terminal glycine in the CP. The
detailed coupling procedure and characterization of the inter-
mediate conjugates can be found in the ESI† (Fig. S1–S6, ESI†).
The final product was characterized by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) and matrix-
assisted laser desorption/ionization time of flight (MALDI-TOF)
mass spectrometry. Based on the SDS-PAGE and MALDI-TOF
analysis, approximately 25% of the CPs were successfully conjugated
with HBP (Fig. 1d and Fig. S7, ESI†), which corresponds on average
to 45 modified CPs per one T = 3 CCMV capsid. Initially, TEM
imaging was employed to investigate the morphology of the
assemblies formed by HBP modified CPs alone. Negatively
stained spherical VLPs were observed under the TEM micro-
scope, having a diameter of B28 nm, which corresponds well
with the expected dimension of the T = 3 icosahedral capsids
(Fig. 1e and Fig. S9a, ESI†). The presence of dark regions in the
capsid cores indicates that the capsids are empty as the stain is
able to enter the voids.40 Empty CCMV capsids were then
disassembled by dialysis against Tris–HCl buffer (50 mM,
pH = 7.4). Disassembly was confirmed by TEM and DLS mea-
surements, which showed a size shift from 28 nm to 8–9 nm
(Fig. 1f and Fig. S9b, ESI†). The obtained CP solution was then
mixed with heparin in different quantities yielding heparin-
loaded capsids (Fig. 1g).
As observed in Fig. 2a–c and Fig. S12, ESI,† the heparin-
loaded capsid assemblies formed with three different heparin
to protein mass ratios (r = 0.02, 0.22, and 0.44) all had a roughly
spherical morphology and a smaller diameter than the empty
T = 3 capsid (28 nm). For instance, TEM images indicated an
average size of 18.6 nm at r = 0.02 (Fig. 2d). Similar diameters
were observed with the r = 0.22 (18.6 nm) and 0.44 (20.2 nm)
samples (Fig. 2d), matching well with the dimension of T = 1
capsids. The preferential formation of T = 1 capsids has been
observed previously, i.e. when highly negatively charged synthetic
polymers40–43 and nucleic acids were encapsulated in CCMV
VLPs.44,45 The particle size has been shown to depend on the
molecular weight of the encapsulated compound, and commonly
higher molecular weight compounds promote the formation of
larger capsids.40,45 Unlike empty capsids, the heparin-loaded
assemblies did not show dark cores (Fig. 2e), demonstrating that
the capsid voids were filled and successfully loaded with heparin
molecules. Cryo-TEM images of the heparin-loaded capsids
further verified the spherical morphology and B18 nm size of
the complexes and confirmed that the observed structures are
not a result of a drying effect.
Fig. 1 (a) Structure of the major repeating unit of heparin. (b) Drawing of the CCMV capsid (T = 3) structure. (c) Illustration of the Sortase A mediated
coupling of HBP to CP. (d) MALDI-TOF spectrum and SDS-PAGE (inset) of HBP modified CPs. (e) TEM image of empty capsids formed by HBP-modified
CPs. (f) DLS measurements (volume-weighted size distributions) of the empty capsid and free CP. (g) Schematic representation of heparin (yellow chain)
encapsulation by a mixture of CP and HBP modified CP to form T = 1 structures.
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The effect of the amount of heparin on capsid formation was
quantified with fluorescein (FITC) moieties according to a
previously published method.46 Successful heparin-FITC con-
jugation was confirmed with FPLC and nuclear magnetic resonance
(NMR) spectroscopy (Fig. S8, ESI†). Fig. 2g shows that the free CPs
were eluting at 19.6 mL and 17.1 mL. Comparison of the peak areas
revealed that 71% of protein was eluting at the higher elution
volume (19.6 mL, Fig. S11, ESI†), which corresponds to the protein
dimers. These values are well in line with previously published work
conducted under similar conditions where the CP dimers were
eluting at 18.5 mL.42 In the present studies, another peak at
17.1 mL, corresponding to slightly larger capsomers, was also
observed.47 The assembled capsids were expected to elute at
lower volumes, and for the r = 0.02 sample, a minor broad peak
appeared around 13.9 mL (Fig. 2g), which corresponds to T = 1
capsids.42 When heparin concentration was increased to r =
0.22, the peak fraction at 13.9 mL increased from 6% to 37%,
showing the formation of more T = 1 capsids. However, further
addition of heparin (r = 0.44) did not significantly increase the
fraction of T = 1 capsids. Instead it enhanced the amount of the
intermediate particles as observed by the larger peak area
between 17.1 mL and 13.9 mL. Additionally, unbound heparin
(peak at 22.4 mL) started to appear (Fig. S12d, ESI†), indicating
that the excess of heparin did not induce further formation of
capsids. This finding is supported by previous studies, which
have shown that capsid formation depends on the amount of
the encapsulated compound and that high cargo ratios limit
capsid formation.41,42 Fractions corresponding to the T = 1
capsids (13 mL) were collected and investigated with the help
of fluorescence spectroscopy measurements. A clear emission
spectrum from the fluorescein-conjugated heparin was observed
for all the heparin-loaded samples, while that for pure heparin-
FITC was neglectable, demonstrating that the encapsulations had
been successful (Fig. 2g inset and Fig. S13, ESI†).
The selectivity of the heparin encapsulation was evaluated
qualitatively with DLS. Studies aimed at encapsulating other
negatively charged target molecules were conducted with two
glycosaminoglycan analogues, i.e. hyaluronic acid and chondroitin
sulfate as well as bovine serum albumin. No size change was
observed when these compounds were added to CCMV CPs (r =
0.02–0.22), indicating that capsids or other higher-order structures
are not formed (Fig. 3a). However, adding heparin in similar mass
ratio clearly induced T = 1 capsid formation, which is visible as a
peak between the CP dimers and T = 3 capsid (Fig. 3b and Fig. S14,
ESI†). Adding heparin to the preassembled T = 3 capsid did not
result in any changes in the size distribution indicating that
heparin is not bound to the exterior of the capsid. Such observa-
tion is expected since the empty capsid remains assembled only at
pH 5 in the presence of high electrolyte concentration (500 mM
NaCl and 10 mM MgCl2), which efficiently screens electrostatic
interactions.
Furthermore, we found negligible hemolytic activity of the
CPs up to 0.5 mg mL1 concentration on red blood cells (RBCs)
(Fig. 3c), which is in sharp contrast to the effect of commonly
employed protamine sulfate, thus providing a promising strategy
in heparin neutralization.
In conclusion, we have shown that CCMV capsid proteins
modified with a heparin-binding peptide exhibit specific heparin
Fig. 2 TEM images of heparin-loaded capsids at (a) r = 0.02, (b) r = 0.22, (c) r = 0.44. (d) Analysis of the dimensions of the complexes (r = 0.02–0.44)
and capsids before disassembly (r = 0), as derived from the TEM images. Solid curves show Gaussian fits. (e) Averaged (n = 40) particle images (size 50 nm 
50 nm), as taken from panels a–c (left) and their 3D intensity profiles (right). (f) Cryo-TEM image of heparin-loaded capsids at r = 0.16. (g) FPLC
chromatogram (280 nm) of free CPs and heparin-loaded capsids (r = 0.02–0.44). Free CPs elute at 19.6 mL and 17.1 mL, and T = 1 heparin-loaded
capsids elute at 13.9 mL. Inset graph shows the fluorescence emission spectrum (excitation at 485 nm) of the heparin-loaded capsids (r = 0.22, green
line) and pure heparin-FITC (black dashed line) collected at the 13.9 mL.
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binding at physiological pH’s. Co-assembly with heparin yielded
T = 1 capsids with diameters ranging between 18–20 nm according
to the DLS measurements and TEM characterization. FPLC results
further confirmed the capsid formation and revealed a heparin
concentration-limiting effect on capsid formation. The binding of
heparin was proved to be specific as no capsid formation was
induced with two other glycosaminoglycan analogs. Moreover,
hemolysis assays demonstrated a better biocompatibility than
the commercial heparin antidote protamine sulfate. These
results indicate that VLPs are promising materials for heparin
binding, especially when the binding is further optimized
for physiological conditions and after thorough hematologic
studies have been conducted.
Conflicts of interest
The authors declare no conflicts of interest.
Acknowledgements
We gratefully thank the Academy of Finland (projects 308578,
303804, 267497), the Jane and Aatos Erkko Foundation, the
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